Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.78 USD | +2.21% | +15.08% | -21.65% |
15/04 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
25/03 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.65% | 2.24B | |
+24.84% | 48.09B | |
+47.30% | 40.62B | |
-2.78% | 40.43B | |
-6.95% | 28.36B | |
+7.75% | 24.89B | |
-19.55% | 19.01B | |
+28.96% | 12.09B | |
-0.75% | 11.88B | |
-0.55% | 11.8B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Intellia Therapeutics, Regeneron Therapeutics Deliver Positive Early-Stage Data on ATTR Amyloidosis Treatment